La genética como factor pronóstico y terapéutico en el mieloma múltiple

• Guillermo Conte L ^[1] ; Esteban Braggio ^[2] ; Gastón Figueroa ^[1] ; Rafael Fonseca ^[3]
  1. [1] Universidad de Chile

     Universidad de Chile

     Santiago, Chile

     
  2. [2] Mayo Clinic Scottsdale Collaborative Research Building
  3. [3] Mayo Clinic Comprehensive Cancer Center Division of Hematology and Oncology

  Mostrar afiliaciones +
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 137, Nº. 4, 2009, págs. 552-558
• Idioma: español
• Títulos paralelos:
  • Genetic markers as prognostic factors in multiple myeloma
• Enlaces
  • Texto completo
• Resumen

  • The search for prognostic factors in multiple myeloma has identified the genetic profile of the tumor as the main determinant of patient survival and response to treatment. There is an association between a dismal prognosis and the presence of t(4:14) translocations or 17p deletion, determined by fluorescent in situ hybridization (FISH) or the detection of chromosome 13 deletion using conventional cytogenetic techniques. These alterations define a subpopulation that comprises 25% of patients with a bad prognosis even if they are treated with high dose chemotherapy These patients should be early derived to more specific therapies. In the other hand, the other 75% of patients without a genetic risk factor, have a higher probability of success with conventional treatment.